Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TBAJ-876,Pretomanid,Linezolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Australian Government
Deal Size : $11.0 million
Deal Type : Funding
Australian Government Grants TB Alliance for Drug-Resistant TB Research
Details : Funding supports the NC-009 Pan-Phase 2 trial of TBAJ-876 combined with pretomanid and linezolid for treating drug-sensitive and resistant tuberculosis.
Brand Name : TBAJ-876
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 24, 2024
Lead Product(s) : TBAJ-876,Pretomanid,Linezolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Australian Government
Deal Size : $11.0 million
Deal Type : Funding
Lead Product(s) : TBAJ-876,Pretomanid,Linezolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
TB Alliance Launches Five-Country Phase 2 Clinical Trial Evaluating Next-Generation TB Drug
Details : TBAJ-876 is a diarylquinoline antibiotic that targets a key enzyme of TB bacteria involved in energy production, it is being evaluated in combination with pretomanid and linezolid, for the treatment for both drug-sensitive and drug-resistant TB.
Brand Name : TBAJ-876
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 16, 2023
Lead Product(s) : TBAJ-876,Pretomanid,Linezolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pretomanid,Bedaquiline,Linezolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Partnership
TB Alliance and Lupin Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB
Details : Lupin intends to commercialize the anti-tuberculosis (TB) medicine, Pretomanid, in approximately 140 countries and territories, including many of the highest TB burden countries around the world.
Brand Name : PA-824
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 06, 2021
Lead Product(s) : Pretomanid,Bedaquiline,Linezolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Cefiderocol,Linezolid
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : U.S.FDA has approved a supplemental New Drug Application for FETROJA® (cefiderocol) for the treatment of patients 18 years of age or older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
Brand Name : Fetroja
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 28, 2020
Lead Product(s) : Cefiderocol,Linezolid
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pretomanid,Bedaquiline,Linezolid
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The new drug was authorised as part of a three-drug, six month, all-oral regimen for the treatment of adults with extensively drug-resistant TB (XDR-TB) or multidrug-resistant TB (MDR-TB) who are treatment-intolerant or non-responsive.
Brand Name : PA-824
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 03, 2020
Lead Product(s) : Pretomanid,Bedaquiline,Linezolid
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cefiderocol,Linezolid
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : FDA has accepted the company’s supplemental New Drug Application (sNDA) for FETROJA® (cefiderocol) and granted Priority Review designation with a Prescription Drug User Fee Act (PDUFA) date of September 27, 2020.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2020
Lead Product(s) : Cefiderocol,Linezolid
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?